Fibrocell Science Inc

Fibrocell Science — OneMedForum (January 2013)

32 slides from Fibrocell Science's conference presentation, Jan 9, 2013

  1. Slide 1: Fibrocell Science - OneMedForum, January 9, 2013

    G) FIBROCE A SCIENCE OneMedForum A | January 9, 2013 aa

  2. Slide 2: Forward Looking Statement

    2 Forward Looking Statement This presentation includes statements that are "forward-looking statements." Forward-looking statements include, without limitation, our ability (i) to obtain medical reimbursement for new non-aesthetic indications, (ii) to timely commence our clinical programs in 2013 to

  3. Slide 3: Unlocking the Potential of the Autologous Fibroblast

    Unlocking the Potential of the Autologous Fibroblast

  4. Slide 4: Fibrocell - Uniquely Positioned in Regenerative Medicine & Cell Based Therapies

    Fibrocell - Uniquely Positioned in Regenerative Medicine & Cell Based Therapies The first and only cell based product in aesthetics laViv(r) - one of only 8 cell based products approved by the FDA laViv(r) - evaluated in over 1,000 patients in well controlled clinical trials Robust pipeline and clin

  5. Slide 5: Role of the Fibroblast Cell

    Role of the Fibroblast Cell Role of the Fibroblast Cell A fibroblast is a type of cell that synthesizes the extracellular matrix and collagen, the structural framework for animal tissues, and plays a critical role in wound healing Fibroblasts are the most common cells of connective tissue in animals

  6. Slide 6: Dermal Fibroblasts Synthesize and Organize Extracellular Matrix

    Dermal fibroblasts produce: Collagen type I Collagen type III Collagen type VII Elastin Hyaluronic acid (hyaluronin) Matrix metalloproteinases (MMPs) Dermal Fibroblasts Synthesize and Organize Extracellular Matrix Artist's interpretation

  7. Slide 7: Fibroblast Location in Skin

    e)) FIBROCELL Fibroblast Location in Skin G RORHER Close-up view | of fibroblasts (collagen-producing cells) 9

  8. Slide 8: Key Focus Areas

    Key Focus Areas Aesthetic Dermatology: Launched the first and only FDA approved, cell based therapy in aesthetics Developed a personalized topical cosmetic Markets where scars are unacceptable, value per cell is increased, and COGS is less of an issue: Restrictive Burn Scars (RBS) 45,000 people hosp

  9. Slide 9: Preclinical Programs

    Preclinical Programs Rare and ultra rare markets where GM (genetically modified) fibroblasts may significantly improve patients well being Initial target is recessive dystrophic epidermolysis bullosa (RDEB) a rare devastating disease Epidermolysis bullosa is a group of genetic conditions that cause

  10. Slide 10: Aesthetic Indication is a Beachhead for Higher Value Indications

    Aesthetics Cell Therapies for Niche Medical Indications (Scars) Cell Therapies for Rare and Ultra Rare Diseases Higher Value Per Cell 45,000 people hospitalized each year with severe burns(1) ~176,778 - 589,260 patients with vocal cord scarring (2) 20 million Americans have acne badly enough to caus

  11. Slide 11: Product Pipeline Status

    Product Pipeline Status Aesthetic (Nasolabial Lines and Other) Approved by the FDA in June 2011 for moderate to severe nasolabial fold wrinkles Acne Scarring In end of Phase II discussions with the FDA and evaluating a path forward Restrictive Burn Scars Phase II study protocol accepted by FDA, stud

  12. Slide 12: Autologous fibroblast therapy for burn scar victims

    Autologous fibroblast cell therapy offers potential functional and aesthetic improvements for burn scar victims Restrictive burn scars are a potential blockbuster indication 45,000 yearly hospitalizations for severe burns (1) Open-label case study for autologous fibroblast therapy in the management

  13. Slide 13: Other Case Studies In Burn Victims

    Other Case Studies In Burn Victims Note: Photos from LAVIV prescribers. Not from clinical studies. Case 1 Case 2

  14. Slide 14: Other Case Studies In Burn Victims

    Other Case Studies In Burn Victims Before 5 Weeks Post Injury 7 Months Post Injury 18 Months Post Injury Area Treated with LAVIV Note: Photos from LAVIV (r)prescribers. Not from clinical studies.

  15. Slide 15: Restrictive Burn Scar Status: Phase II Trial Design

    Phase II Trial Design: Single site, placebo-controlled, 20 subjects Enrollment: Subjects who have unilateral restrictive burn scars of a jointed area (i.e., wrist, elbow, shoulder, knee) with > 20% decrease in normal ROM with no additional improvement after physical therapy Measurement Scales: Range

  16. Slide 16: Vocal cord trauma and dysphonia

    Vocal cord trauma is the most commonly encountered finding in dysphonia (loss of voice) Most often seen after surgery on the vocal folds but can also result from radiation therapy, vocal cord trauma, and idiopathic causes Currently has no effective therapy Positive results in pilot studies Autologou

  17. Slide 17: Vocal Cord Scarring Status: Phase II protocol

    Phase II protocol drafted and under review internally expected to submit to the FDA first half 2013 Proposed Endpoints: Subject's impression of improvement in voice quality (VAS) Change from baseline in the noise-to-harmonic ratio (dB) as measured from acoustic voice analysis Absolute and percentage

  18. Slide 18: Overview of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

    Overview of Recessive Dystrophic Epidermolysis Bullosa (RDEB) Epidermolysis bullosa is a group of genetic conditions that cause the skin to be very fragile and to blister easily Blisters and skin erosions form in response to minor injury or friction, such as rubbing or scratching RDEB: In mild cases

  19. Slide 19: RDEB: Proposed GM fibroblast therapeutic with Intrexon

    Recessive Dystrophic Epidermolysis Bullosa (RDEB) Proposed new therapeutic product: A genetically modified (GM) fibroblast up-regulated to produce Collagen VII in a controlled manner for localized or systemic treatment of RDEB Employ Intrexon's synthetic biology platforms for optimal gene expression

  20. Slide 20: UCLA Collaboration: Stem Cell Program

    UCLA Collaboration: Stem Cell Program

  21. Slide 21: Mesenchymal stem cell subset discovered by Fibrocell

    21 Fibrocell has discovered and purified a subset of Mesenchymal stem cells (MSCs) that can differentiate into different, potentially useful cell-types, such as cells that form bone, fat and cartilage The cells may be used for either in vitro research applications or re-implantation back into the do

  22. Slide 22: Stem Cell Collaboration: Expansion of Isolated MSCs and IPSCs

    Stem Cell Collaboration Expansion of Isolated MSCs and IPSCs Background After characterizing UCLA MSC and IPSC dermal fibroblast subpopulations, scientists determined a commercially viable method for maintenance and expansion of the specialized cells is required Fibrocell has entered into a collabor

  23. Slide 23: Personalized Cosmetic Development

    Personalized Cosmetic Development

  24. Slide 24: Product Overview

    Product Overview A novel, high quality moisturizer Conditioned complete growth media from the azficel-T production process is collected, concentrated and used to formulate a personalized topical cosmetic Blend with an appropriate vehicle cream Specially formulated for Fibrocell Science Contains bota

  25. Slide 25: Clinical Study Status

    Clinical Study Status Cosmetic clinical trial evaluating impact of product on photo damaged skin Single center, 20 subjects Apply product twice a day Evaluated with expert graded scale assessment and photography after two months Enrollment Completed

  26. Slide 26: Manufacturing Capacity Update

    Manufacturing Capacity Update

  27. Slide 27: Manufacturing Capacity Update

    Manufacturing Capacity Update Current autologous cell manufacturing process: Complex and intricate Labor intensive Requires comprehensive quality control checks Requires comprehensive quality assurance practices As cellular therapies grow in use, significant progress is being made in supportive tech

  28. Slide 28: Manufacturing Capacity Update

    Manufacturing Capacity Update Fibrocell has identified technologies that may dramatically reduce manufacturing time, complexity, and labor costs for our cell therapies, both laViv(r) and those in clinical development Pending a full assessment of these technologies we are deferring the previously ann

  29. Slide 29: Financials / Capitalization Table

    Financials / Capitalization Table Strong cash position Large private capital raise completed in October 2012, investor syndicate led by Third Security, an investment firm led by RJ Kirk No debt on the balance sheet Company's capital structure greatly simplified All outstanding preferred stock was co

  30. Slide 30: Fibrocell Capitalization Table

    Financials / Capitalization Table Fibrocell Capitalization Table Common shares 656.7M Warrants 153.3M Options 14.0M Fully Diluted Shares Outstanding 824.1M

  31. Slide 31: Summary

    Summary Fibrocell is uniquely positioned in regenerative medicine & cell based therapies Aesthetic applications are a beachhead for higher value indications Pursuing higher value per cell opportunities: Currently there are no drugs approved for Vocal Cord Scarring, Restrictive Burn Scars and Acne Sc

  32. Slide 32: Summary

    Summary Exploring higher value per cell in rare and ultra rare diseases Prevalence of RDEB is 6.5 per million newborns in the US (1) Currently at least 12 products for other rare diseases have a wholesale cost of $200,000 plus (2) Unlike laViv(r), reimbursement is expected. Currently there are no dr

Fibrocell Science — OneMedForum (January 2013) on 6ix